Drug Search Results
More Filters [+]

Acumapimod

Alternative Names: acumapimod, bct197
Latest Update: 2023-03-21
Latest Update Note: Clinical Trial Update

Product Description

Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD).

Mechanisms of Action: MAP2K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mereo BioPharma
Company Location: LONDON X0 W1G0QF
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Acumapimod

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Chronic Obstructive Pulmonary Disease|Acute Kidney Injury

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MBCT103

P1

Completed

Healthy Volunteers

2018-05-03

MBCT206

P2

Completed

Chronic Obstructive Pulmonary Disease

2017-11-08

2015-004631-13

P2

Completed

Chronic Obstructive Pulmonary Disease

2017-11-07

MBCT102

P1

Completed

Healthy Volunteers

2016-10-01

Recent News Events